Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.48 |
| ▸ | MME | P08473 | 14/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 9/20 | 0.42 |
| ▸ | ACE | P12821 | 6/20 | 0.42 |
| ▸ | CPA1 | P15085 | 6/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489509 | 0.85 | MME (0.51) | LTB4R2MMEAGTR1HDAC3HDAC1 | |
| SCHEMBL489427 | 0.84 | LTB4R2 (0.46) | LTB4R2MMEAGTR1ACECPA1 | |
| SCHEMBL489278 | 0.82 | MMP8 (0.46) | LTB4R2MMEAGTR1HDAC3HDAC1 | |
| SCHEMBL489309 | 0.81 | MME (0.50) | LTB4R2MMEAGTR1ACEHDAC3 | |
| SCHEMBL489537 | 0.78 | LTB4R2 (0.50) | LTB4R2MMEAGTR1ACECPA1 | |
| SCHEMBL489535 | 0.74 | LTB4R2 (0.59) | LTB4R2AGTR1 | |
| SCHEMBL1256410 | 0.69 | AGTR1 (0.63) | MMEAGTR1 | |
| SCHEMBL1256439 | 0.69 | MME (0.83) | MMEAGTR1 | |
| SCHEMBL489834 | 0.68 | MMP8 (0.53) | LTB4R2MMEAGTR1HDAC3HDAC1 | |
| SCHEMBL489727 | 0.66 | MMP8 (0.48) | HDAC3HDAC1HDAC2HDAC8NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236839-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120088919-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8106082-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834041-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2200975-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009035543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | LTB4R2 816/4885MME 5/4885AGTR1 1/4885 |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | LTB4R2 816/4885MME 5/4885AGTR1 1/4885 |
| US-20120088919-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | LTB4R2 816/4885MME 5/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.